Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 24, 2025
Finance
Ascentage lists on NASDAQ as Odyssey, Sionna, Aardvark plot IPOs
In BioCentury’s Finance Report, two more companies plan Hong Kong listings; Disc Medicine, Arctic raise cash
BioCentury | Jun 13, 2024
Discovery & Translation
Science Spotlight: Lyell’s scaffold for reenergizing CAR T cells; plus Cirrus, Denali and more
BioCentury’s roundup of translational innovations
BioCentury | Dec 11, 2023
Product Development
Building on dermatology’s recent success
Targets, mechanisms and indications that stand to benefit from the surging interest in dermatology
BioCentury | Apr 27, 2023
Emerging Company Profile
Evommune: advancing ex-Dermira assets, screening for new programs using human tissue
Backed with $145M since 2020, the biotech has a Phase IIa molecule for atopic dermatitis, plus at least two preclinical programs
BioCentury | Mar 21, 2023
Product Development
March 20 Quick Takes: Latest data add to Karuna’s case in schizophrenia
Plus: two Sangamo partnerships end, Gilead adds Nurix’s degrader
BioCentury | Feb 17, 2023
Discovery & Translation
Engineering bacteria to monitor and treat metabolic disorders; plus on-demand male contraception and more
BioCentury's roundup of translational news
BioCentury | Jan 6, 2023
Product Development
Kornowski shifts gears at Boston Pharma, sets NASH program as top priority
Ex-Roche exec refines focus, decides what to keep and commercialize vs. what to partner out
BioCentury | Dec 15, 2022
Finance
Dec. 14 Quick Takes: Alpha-9 lands $75M for radiopharmaceutical pipeline
Plus: Avidity gains 55% on antibody-oligo conjugate data, and updates from Storm, Avidity, Kymera, Icosavax and more
BioCentury | Apr 5, 2022
Politics, Policy & Law
April 4 Quick Takes: University of California continues CRISPR IP fight
Plus Protalix gains on Fabry data and updates from Alnylam, Curis, Gilead, BMS
BioCentury | Oct 28, 2021
Product Development
Kymera adds to the clinical picture for protein degraders
The company digs into the biological effects of its IRAK4 degrader
Items per page:
1 - 10 of 144